{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T22:49:22Z","timestamp":1793573362841,"version":"4.5.0"},"reference-count":31,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"unspecified","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2022-00756"],"award-info":[{"award-number":["2022-00756"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,4,4]]},"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The human papillomavirus (HPV) vaccine can effectively prevent cervical cancer, yet HPV vaccine uptake is particularly low in some low-income settings, due to supply and vaccine confidence barriers. HPV vaccine confidence has also been found to be lacking among healthcare workers in some countries, including Nigeria. Nigeria has a long history of low vaccine confidence in some parts of the country. HPV vaccine rumours and concerns have been observed throughout the country, including among healthcare workers. Interventions that specifically address healthcare workers\u2019 vaccine confidence are limited, since vaccine confidence is often assumed among this group. The aim of our pilot cluster randomised control trial (cRCT) is to evaluate the feasibility of conducting a trial that evaluates codesigned interventions to improve HPV vaccine confidence in healthcare workers and the acceptability and feasibility of delivering this intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This is a 3-arm pilot cRCT, using a mixed-methods approach to assess the feasibility of the trial design, alongside the feasibility and acceptability of intervention delivery in two states in Nigeria (Jigawa and Oyo). We will implement two interventions: one with a focus on digital delivery, and one with an HPV champion present at a health facility. Both will be compared with a control arm, providing standard information on HPV vaccine only. Overall, 12 trial clusters (six in Jigawa and six in Oyo), defined as government primary healthcare facilities, will be randomised using a 1:1:1 ratio, stratified by state. All healthcare workers within these facilities will be eligible to take part in the intervention and evaluation. The primary outcome of interest will be intervention uptake, as a measure of subsequent trial feasibility given concerns around contamination in control clusters. This will be assessed through an endline healthcare worker survey. Intervention feasibility and acceptability will be assessed through quantitative intervention monitoring and qualitative interviews with healthcare workers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>We received approval from Jigawa State Ethics Committee (ref: JGHREC\/2023\/151), Jigawa Ministry of Health (ref: MOH\/PH\/PHRAT\/MN\/23\/003), Oyo State Research Ethics Review Committee (ref: AD\/13\/479\/362A), The University of Ibandan and University College Hospital Research Ethics Committee (UI\/UCH Ethics Committee) (ref: UI\/EC\/23\/308) and from the Swedish National Ethics Review Board (2023-04772-01-471058). Data will be presented in manuscript form and submitted to relevant conferences for dissemination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration details<\/jats:title>\n                    <jats:p>\n                      The pilot trial has been registered with ISRCTN\u2014the UK\u2019s Clinical Study Registry, registration number\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"isrctn\" xlink:href=\"ISRCTN37847119\">ISRCTN37847119<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-098308","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T16:05:52Z","timestamp":1745337952000},"page":"e098308","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Building HPV vaccine confidence through codesigned interventions with and for healthcare workers in Nigeria: protocol for a pilot cluster randomised controlled trial"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"isrctn37847119","registry":"10.18810\/isrctn"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5270-1170","authenticated-orcid":false,"given":"Sibylle","family":"Herzig van Wees","sequence":"first","affiliation":[{"name":"Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2456-7899","authenticated-orcid":false,"given":"Ayobami Adebayo","family":"Bakare","sequence":"additional","affiliation":[{"name":"Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Community Medicine, University College Hospital, Ibadan, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kofoworola O.","family":"Akinsola","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, University of Ibadan, Ibadan, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius","family":"Salako","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, University of Ibadan, Ibadan, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damola","family":"Bakare","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, University of Ibadan, Ibadan, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Gobbo","sequence":"additional","affiliation":[{"name":"Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8066-7873","authenticated-orcid":false,"given":"Claudia","family":"Hanson","sequence":"additional","affiliation":[{"name":"Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adegoke G","family":"Falade","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, University College Hospital, Ibadan, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"King","sequence":"additional","affiliation":[{"name":"Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"key":"2025120721563480000_15.4.e098308.1","doi-asserted-by":"crossref","first-page":"F12","DOI":"10.1016\/j.vaccine.2012.07.055","article-title":"Global burden of human papillomavirus and related diseases","volume":"30 Suppl 5","author":"Forman","year":"2012","journal-title":"Vaccine (Auckl)"},{"key":"2025120721563480000_15.4.e098308.2","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.virol.2008.11.046","article-title":"Papillomaviruses in the causation of human cancers - a brief historical account","volume":"384","author":"zur Hausen","year":"2009","journal-title":"Virology (Auckl)"},{"key":"2025120721563480000_15.4.e098308.3","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30716"},{"key":"2025120721563480000_15.4.e098308.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917338"},{"key":"2025120721563480000_15.4.e098308.5","doi-asserted-by":"publisher","DOI":"10.1016\/s2214-109x(16)30099-7"},{"key":"2025120721563480000_15.4.e098308.6","unstructured":"SAGE Working Group . Report of the Sage working group on vaccine hesitancy. 2014."},{"key":"2025120721563480000_15.4.e098308.7","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-023-15842-1","article-title":"Barriers and facilitators of HPV vaccination in sub-saharan Africa: a systematic review","volume":"23","author":"Kutz","year":"2023","journal-title":"BMC Public Health"},{"key":"2025120721563480000_15.4.e098308.8","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2326295","article-title":"Human papillomavirus vaccination uptake and determinant factors among adolescent schoolgirls in sub-Saharan Africa: A systematic review and meta-analysis","volume":"20","author":"Asgedom","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"2025120721563480000_15.4.e098308.9","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1564436"},{"key":"2025120721563480000_15.4.e098308.10","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2402122","article-title":"Healthcare worker practices for HPV vaccine recommendation: A systematic review and meta-analysis","volume":"20","author":"Bakare","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"2025120721563480000_15.4.e098308.11","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1016\/j.vaccine.2015.04.040","article-title":"Strategies for addressing vaccine hesitancy - A systematic review","volume":"33","author":"Jarrett","year":"2015","journal-title":"Vaccine (Auckl)"},{"key":"2025120721563480000_15.4.e098308.12","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2431380","article-title":"How has co-design been used to address vaccine hesitancy globally? A systematic review","volume":"20","author":"Alpeza","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"2025120721563480000_15.4.e098308.13","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2024.29.9.2300276","article-title":"Effectiveness of interventions to increase healthcare workers\u2019 adherence to vaccination against vaccine-preventable diseases: a systematic review and meta-analysis, 1993 to 2022","volume":"29","author":"Clari","year":"2024","journal-title":"Euro Surveill"},{"key":"2025120721563480000_15.4.e098308.14","doi-asserted-by":"crossref","first-page":"6438","DOI":"10.1016\/j.vaccine.2017.09.075","article-title":"Understanding vaccine hesitancy in polio eradication in northern Nigeria","volume":"35","author":"Taylor","year":"2017","journal-title":"Vaccine (Auckl)"},{"key":"2025120721563480000_15.4.e098308.15","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2021-006002","article-title":"30 years of polio campaigns in Ethiopia, India and Nigeria: the impacts of campaign design on vaccine hesitancy and health worker motivation","volume":"6","author":"Neel","year":"2021","journal-title":"BMJ Glob Health"},{"key":"2025120721563480000_15.4.e098308.16","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/S0140-6736(04)16380-0","article-title":"Polio-vaccination boycott in Nigeria","volume":"363","author":"Olusanya","year":"2004","journal-title":"The Lancet"},{"key":"2025120721563480000_15.4.e098308.17","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101499","article-title":"COVID-19 vaccine hesitancy amongst healthcare workers: An assessment of its magnitude and determinants during the initial phase of national vaccine deployment in Nigeria","volume":"50","author":"Nomhwange","year":"2022","journal-title":"EClinicalMedicine"},{"key":"2025120721563480000_15.4.e098308.18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.36519\/idcm.2024.375","article-title":"The COVID-19 Vaccine Hesitancy Among Healthcare Workers: An Exploration of Hesitancy Reasons and Suggestions to Improve Vaccination Rates","volume":"6","author":"Madran","year":"2024","journal-title":"Infect Dis Clin Microbiol"},{"key":"2025120721563480000_15.4.e098308.19","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/j.puhe.2021.01.010","article-title":"COVID-19 vaccine rollout: will it affect the rates of vaccine hesitancy in Africa?","volume":"197","author":"Ekwebelem","year":"2021","journal-title":"Public Health (Fairfax)"},{"key":"2025120721563480000_15.4.e098308.20","unstructured":"Arce JSS , Warren SS , Meriggi NF , et al . COVID-19 vaccine acceptance and hesitancy in low and middle income countries, and implications for messaging. medRxiv 2021. Available: https:\/\/www.medrxiv.org\/content\/10.1101\/2021.03.11.21253419v1"},{"key":"2025120721563480000_15.4.e098308.21","unstructured":"World Bank Group . Population, total - Nigeria | data. 2023. Available: https:\/\/data.worldbank.org\/indicator\/SP.POP.TOTL?locations=NG [Accessed 30 Oct 2024]."},{"key":"2025120721563480000_15.4.e098308.22","unstructured":"UNICEF . Levels and trends in child mortality. 2020. Available: https:\/\/www.unicef.org\/reports\/levels-and-trends-child-mortality-report-2020 [Accessed 31 Oct 2024]."},{"key":"2025120721563480000_15.4.e098308.23","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S1470-2045(24)00206-7","article-title":"Nigeria revitalises national cancer response with new initiatives","volume":"25","author":"Adepoju","year":"2024","journal-title":"Lancet Oncol"},{"key":"2025120721563480000_15.4.e098308.24","unstructured":"WHO Africa Regional Office, World Health Organization . Nigeria to vaccinate 7.7 million girls against leading cause of cervical cancer. 2023. Available: https:\/\/www.afro.who.int\/countries\/nigeria\/news\/nigeria-vaccinate-77-million-girls-against-leading-cause-cervical-cancer"},{"key":"2025120721563480000_15.4.e098308.25","unstructured":"GAVI . Nigeria\u2019s kwara state rolls out HPV vaccine to enthusiastic reception. 2024. Available: https:\/\/www.gavi.org\/vaccineswork\/kwara-state-rolls-out-hpv-vaccine-enthusiastic-reception [Accessed 29 Oct 2024]."},{"key":"2025120721563480000_15.4.e098308.26","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2147\/IJWH.S44483","article-title":"Mothers\u2019 human papilloma virus knowledge and willingness to vaccinate their adolescent daughters in Lagos, Nigeria","volume":"5","author":"Ezenwa","year":"2013","journal-title":"Int J Womens Health"},{"key":"2025120721563480000_15.4.e098308.27","doi-asserted-by":"crossref","first-page":"112","DOI":"10.11604\/pamj.2020.36.112.19007","article-title":"Parental willingness to vaccinate adolescent daughters against human papilloma virus for cervical cancer prevention in Western Nigeria","volume":"36","author":"Akinleye","year":"2020","journal-title":"Pan Afr Med J"},{"key":"2025120721563480000_15.4.e098308.28","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines12010084","article-title":"Determinants of Human Papillomavirus Vaccine Acceptance among Caregivers in Nigeria: A Fogg Behavior Model-Based Approach","volume":"12","author":"Agha","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"2025120721563480000_15.4.e098308.29","unstructured":"NPC, ICF . Nigeria demographic and health survey 2024 - final report. 2024. Available: https:\/\/dhsprogram.com\/methodology\/survey\/survey-display-609.cfm [accessed 18 Feb 2025]"},{"key":"2025120721563480000_15.4.e098308.30","doi-asserted-by":"crossref","DOI":"10.2196\/jmir.5927","article-title":"IDEAS (Integrate, Design, Assess, and Share): A Framework and Toolkit of Strategies for the Development of More Effective Digital Interventions to Change Health Behavior","volume":"18","author":"Mummah","year":"2016","journal-title":"J Med Internet Res"},{"key":"2025120721563480000_15.4.e098308.31","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2322796","article-title":"A systematic review of measures of healthcare workers\u2019 vaccine confidence","volume":"20","author":"Akinsola","year":"2024","journal-title":"Hum Vaccin Immunother"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-098308","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T05:57:25Z","timestamp":1765173445000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-098308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,22]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1136\/bmjopen-2024-098308"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-098308","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}